Article
Stepwise evolution of therapy resistance in AML.
Cancer cell - 12 Jul 2021
Gui Philippe, Bivona Trever G
Abstract excerpt
Relapse of AML patients to FLT3i treatment is the result of a long-term and stepwise process leading to resistance, whereby residual cancer cells initially survive and subsequently expand. Here, Joshi et al. use a multifaceted approach to characterize how microenvironment-driven early resistance to gilteritinib evolves into mutation-driven late resistance.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.